Findings

What do systematic reviews say?

11 questions · 11 findings · 2 reviews · Hepato-Biliary

Sort:Best matchNewest Highest certainty Download CSV

No studies found 9 · 81.8%GRADE not reported 0 · 0%Very low 2 · 18.2%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Gemcitabine vs vandetanib

Time to progression of the tumour · people with advanced biliary tract carcinomas

The review found no eligible studies for this question.

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gemcitabine plus cisplatin vs S‐1 plus cisplatin

Time to progression of the tumour · people with advanced biliary tract carcinomas

The review found no eligible studies for this question.

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gemcitabine plus S‐1 vs S‐1

Time to progression of the tumour · people with advanced biliary tract carcinomas

The review found no eligible studies for this question.

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gemcitabine plus oxaliplatin vs best supportive care

Time to progression of the tumour · people with advanced biliary tract carcinomas

The review found no eligible studies for this question.

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gemcitabine plus oxaliplatin vs 5‐fluorouracil plus folinic acid

Time to progression of the tumour · people with advanced biliary tract carcinomas

The review found no eligible studies for this question.

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gemcitabine plus oxaliplatin vs 5‐fluorouracil plus cisplatin plus radiotherapy

Time to progression of the tumour · people with advanced biliary tract carcinomas

The review found no eligible studies for this question.

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gemcitabine plus mitomycin C vs capecitabine plus mitomycin C

Time to progression of the tumour · people with advanced biliary tract carcinomas

The review found no eligible studies for this question.

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gemcitabine plus vandetanib vs vandetanib

Time to progression of the tumour · people with advanced biliary tract carcinomas

The review found no eligible studies for this question.

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Radioembolisation vs sorafenib monotherapy

Time to progression of the tumour · people with hepatocellular carcinoma

1 finding from 1 review

Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 360 participants
Very low

Radioembolisation vs chemoembolisation

Time to progression of the tumour · people with hepatocellular carcinoma

1 finding from 1 review

Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 97 participants
Very low

Radioembolisation plus sorafenib vs sorafenib monotherapy

Time to progression of the tumour · people with hepatocellular carcinoma

The review found no eligible studies for this question.

1 finding from 1 review

Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found